BRPI0822238B8 - composições compreendendo ácidos graxos insaturados e compostos liberadores de óxido nítrico - Google Patents

composições compreendendo ácidos graxos insaturados e compostos liberadores de óxido nítrico

Info

Publication number
BRPI0822238B8
BRPI0822238B8 BRPI0822238A BRPI0822238A BRPI0822238B8 BR PI0822238 B8 BRPI0822238 B8 BR PI0822238B8 BR PI0822238 A BRPI0822238 A BR PI0822238A BR PI0822238 A BRPI0822238 A BR PI0822238A BR PI0822238 B8 BRPI0822238 B8 BR PI0822238B8
Authority
BR
Brazil
Prior art keywords
compositions
fatty acids
preventing
nitric oxide
unsaturated fatty
Prior art date
Application number
BRPI0822238A
Other languages
English (en)
Portuguese (pt)
Inventor
Pan Yuanlong
Original Assignee
Nestec Sa
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0822238(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa, Nestle Sa filed Critical Nestec Sa
Publication of BRPI0822238A2 publication Critical patent/BRPI0822238A2/pt
Publication of BRPI0822238B1 publication Critical patent/BRPI0822238B1/pt
Publication of BRPI0822238B8 publication Critical patent/BRPI0822238B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
BRPI0822238A 2008-01-04 2008-12-19 composições compreendendo ácidos graxos insaturados e compostos liberadores de óxido nítrico BRPI0822238B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1009708P 2008-01-04 2008-01-04
US61/010,097 2008-01-04
US13738208P 2008-07-30 2008-07-30
US61/137,382 2008-07-30
PCT/US2008/013870 WO2009088433A1 (en) 2008-01-04 2008-12-19 Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions

Publications (3)

Publication Number Publication Date
BRPI0822238A2 BRPI0822238A2 (pt) 2015-06-30
BRPI0822238B1 BRPI0822238B1 (pt) 2020-03-10
BRPI0822238B8 true BRPI0822238B8 (pt) 2021-05-25

Family

ID=40853324

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822238A BRPI0822238B8 (pt) 2008-01-04 2008-12-19 composições compreendendo ácidos graxos insaturados e compostos liberadores de óxido nítrico

Country Status (11)

Country Link
US (4) US20100233304A1 (enExample)
EP (2) EP2224930B1 (enExample)
JP (1) JP5979816B2 (enExample)
CN (2) CN101909632A (enExample)
AU (1) AU2008347177B2 (enExample)
BR (1) BRPI0822238B8 (enExample)
CA (2) CA2709660C (enExample)
ES (2) ES2586757T3 (enExample)
MX (1) MX337760B (enExample)
RU (1) RU2500402C2 (enExample)
WO (1) WO2009088433A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
EP1888510A4 (en) 2005-05-27 2013-01-16 Univ North Carolina NITROGEN OXIDE-RELATED PARTICLES FOR NITROGEN OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS
US20100292330A1 (en) * 2007-10-04 2010-11-18 Yuanlong Pan Compositions and methods for enhancing cognitive function
CN102170792A (zh) * 2008-07-18 2011-08-31 希尔氏宠物营养品公司 提高老龄动物生活质量的方法
AU2013200758B2 (en) * 2008-07-18 2014-06-12 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
CA2773523A1 (en) * 2009-09-11 2011-03-17 Nestec S.A. Compositions and methods for enhancing cognitive and related functions in animals
WO2011081509A1 (es) * 2009-12-29 2011-07-07 Chavez Gabriela Composiciones nutricionales que comprenden hojuelas de frutas que incluyen ácido docosahexaenoico
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CN102552457A (zh) * 2010-12-24 2012-07-11 漆又毛 一种氨基酸和提取物组合物的药物用途
ES2828479T3 (es) 2011-01-25 2021-05-26 Nestle Sa Métodos y composiciones para tratar, reducir o prevenir el deterioro del sistema visual de los animales
JP2014514248A (ja) * 2011-02-18 2014-06-19 ネステク ソシエテ アノニム 動物の神経系への損傷を治療、軽減、又は予防するための方法及び組成物
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
ES2727043T3 (es) * 2011-03-18 2019-10-11 Nestle Sa Composiciones y métodos útiles para mejorar enfermedades relacionadas con la edad
AT511776B1 (de) * 2011-07-26 2014-03-15 Gonadosan Gmbh Verwendung von citrullin und ein kombinationspräparat zur verbesserung der männlichen fertilität
US20130059028A1 (en) * 2011-09-01 2013-03-07 Julie Marie Foy Compositions and Methods for Providing a Life-Stage-Appropriate Animal Diet
CN102600124B (zh) * 2012-02-06 2014-03-26 单宝华 Omega-3增强组合物及其应用
WO2014069666A1 (en) * 2012-10-30 2014-05-08 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN103609752B (zh) * 2013-12-02 2016-05-25 内蒙古伊利实业集团股份有限公司 一种改善脑部认知功能的组合物及其制备方法与应用
US20160341708A1 (en) * 2013-12-19 2016-11-24 Hill's Pet Nutrition, Inc. Method for determining spoilage of high protein foods
WO2015160234A1 (en) * 2014-04-17 2015-10-22 N.V. Nutricia Composition for brain improvement
MX2017004662A (es) * 2014-10-10 2017-07-26 Nestec Sa Composiciones y metodos para mejorar la movilidad o actividad o tratar la fragilidad.
CA2964858C (en) * 2014-10-22 2023-10-24 Raffaele Migliaccio Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
US20180000118A1 (en) * 2014-12-29 2018-01-04 Hill's Pet Nutrition, Inc. Food Composition and Method of Use
EP3310349B1 (en) 2015-06-22 2021-01-13 Société des Produits Nestlé S.A. Compositions and methods for enhancing neurogenesis in animals
CN105602998A (zh) * 2016-01-18 2016-05-25 青岛哈拿生物科技有限公司 一种水溶性天然一氧化氮的制作方法及应用
EP3463321A1 (en) * 2016-05-27 2019-04-10 Nestec S.A. Nutritional composition for treating or preventing impaired mobility
MX385552B (es) * 2016-09-29 2025-03-18 Soc Des Produits Nestle S A Star Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia.
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
EP3595646A4 (en) * 2017-03-18 2021-01-13 McGarrah, Steven, M. PET FOOD WITH CANNABIDIOLIC ACID
BR112019017949A2 (pt) * 2017-04-11 2020-05-19 Nestle Sa níveis de ácidos graxos ômega-3 e vitamina d para identificar e atenuar o envelhecimento cognitivo em indivíduos
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
WO2022191184A1 (ja) * 2021-03-08 2022-09-15 国立大学法人九州大学 グレリン受容体感受性増強剤、グレリン受容体感受性増強用組成物及びグレリン受容体の活性化方法
EP4449875A1 (en) 2023-04-18 2024-10-23 Mars, Incorporated Composition for use for improving or preserving mental health in canine

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2018A (en) * 1841-03-26 Joseph francis
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
IT1264987B1 (it) * 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
HUP9800049A3 (en) † 1995-02-23 1999-01-28 Novartis Nutrition Ag Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf
US5910307A (en) 1996-09-19 1999-06-08 Sunkyong Industries, Ltd. Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
EP1233670B1 (en) * 1999-06-14 2008-09-17 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US7135498B1 (en) * 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
JP4669095B2 (ja) 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
US8124589B2 (en) * 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US20040043013A1 (en) * 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20050002992A1 (en) † 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements
CA2441192C (en) 2001-03-23 2009-05-19 Ajinomoto Co., Inc. The use of lysine for the prevention or treatment of stress-induced diseases
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
DE10131516B4 (de) † 2001-07-02 2004-05-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Steuereinheit zur Flussregulierung
US6967219B2 (en) * 2001-10-12 2005-11-22 Cornell Research Foundation, Inc. Reversing or preventing premature vascular senescence
NL1019368C2 (nl) † 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
MXPA05009933A (es) 2003-03-18 2005-11-04 Novartis Ag Composiciones que comprenden acidos grasos y aminoacidos.
DK1641351T3 (da) † 2003-07-03 2014-08-25 Hills Pet Nutrition Inc Sammensætninger og fremgangsmåder til at formindske aldersrelateret forringelse af mental aktivitet hos familiedyr
US6951658B1 (en) † 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
JP4699901B2 (ja) * 2003-09-02 2011-06-15 ジェレックスインターナショナル株式会社 体脂肪代謝機能と燃焼エネルギーの活用機能とを備えているダイエット用添加物質
JPWO2005061684A1 (ja) † 2003-12-22 2007-12-13 湧永製薬株式会社 油脂組成物
US20060002985A1 (en) † 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
CA2592389C (en) 2004-12-29 2013-05-14 Hill's Pet Nutrition, Inc. Methods for inhibiting a decline in learning and/or memory in animals
AU2005322887B2 (en) 2004-12-30 2010-03-11 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
WO2006072084A2 (en) 2004-12-30 2006-07-06 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a growing animal
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
CN1810257A (zh) * 2005-05-26 2006-08-02 钟健琳 活脑素口服液
WO2007004148A2 (en) 2005-06-30 2007-01-11 Koninklijke Philips Electronics N.V. Method and system for selection of information
BRPI0613358A8 (pt) † 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
US20070053955A1 (en) † 2005-08-26 2007-03-08 Nestec S.A. Compositions and methods for improving cellular survival and reducing apoptosis after ischemic episode in the brain
AU2006299665B2 (en) 2005-09-30 2012-12-13 Nestec S.A. Methods and compositions for improving cognitive function
EP1955698B1 (en) † 2005-12-02 2013-10-30 Mochida Pharmaceutical Co., Ltd. Preventive/therapeutic agent for alzheimer's dementia
EP1800675B1 (en) † 2005-12-23 2011-05-18 N.V. Nutricia Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
US20100292330A1 (en) 2007-10-04 2010-11-18 Yuanlong Pan Compositions and methods for enhancing cognitive function
WO2014100896A1 (en) 2012-12-31 2014-07-03 Aastra Technologies Limited Interface adapter

Also Published As

Publication number Publication date
CA2709660C (en) 2018-06-05
CA2709660A1 (en) 2009-07-16
EP3058942B2 (en) 2023-03-22
US11951137B2 (en) 2024-04-09
EP2224930A4 (en) 2011-06-22
US20170157182A1 (en) 2017-06-08
ES2586757T3 (es) 2016-10-18
EP2224930A1 (en) 2010-09-08
EP3058942A1 (en) 2016-08-24
US20190030088A1 (en) 2019-01-31
CA2994586A1 (en) 2009-07-16
US20210205373A1 (en) 2021-07-08
AU2008347177A1 (en) 2009-07-16
ES2773928T3 (es) 2020-07-15
EP3058942B1 (en) 2019-12-04
AU2008347177B2 (en) 2014-04-17
US10973859B2 (en) 2021-04-13
MX337760B (es) 2016-03-17
JP2011508773A (ja) 2011-03-17
BRPI0822238B1 (pt) 2020-03-10
US10111911B2 (en) 2018-10-30
JP5979816B2 (ja) 2016-08-31
RU2500402C2 (ru) 2013-12-10
RU2010132637A (ru) 2012-02-10
WO2009088433A1 (en) 2009-07-16
CN105267969A (zh) 2016-01-27
ES2773928T5 (es) 2023-06-28
EP2224930B1 (en) 2016-06-15
US20100233304A1 (en) 2010-09-16
BRPI0822238A2 (pt) 2015-06-30
CN101909632A (zh) 2010-12-08
CA2994586C (en) 2020-07-21

Similar Documents

Publication Publication Date Title
BRPI0822238B8 (pt) composições compreendendo ácidos graxos insaturados e compostos liberadores de óxido nítrico
MX2010003568A (es) Composiciones y metodos para mejorar la funcion cognitiva.
BR112021021301A2 (pt) Derivados de ácido itacônico e usos dos mesmos no tratamento de uma doença inflamatória ou de uma doença associada a uma resposta imune indesejável
WO2011031304A3 (en) Compositions and methods for enhancing cognitive and related functions in animals
MX394103B (es) Anticuerpos anti-angptl8 y usos de estos.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
ATE549394T1 (de) Für tiere geeignete probiotische zusammensetzung
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
EA201591754A1 (ru) Человеческие антитела к na1.7
NZ778131A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EA201790377A1 (ru) Антитела к глюкагону и их применения
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
EA201270566A1 (ru) Противомикробные соединения и способы их получения и применения
MX380725B (es) Composiciones de urolitidina para mejorar la función mitocondrial y tratar condiciones patológicas relacionadas a los músculos
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
EA201391536A1 (ru) Противомикробные соединения и способы их получения и применения
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MY149171A (en) Treatment and prevention of influenza
MX2015016120A (es) Moleculas de union que se adhieren al factor de complemento c2 humano y usos de los mismos.
WO2014054981A3 (ru) Способ стимуляции роста и повышения резистентности сельскохозяйственных животных
EA201500913A1 (ru) Противомикробные соединения и способы их получения и применения
BR112016010159A2 (pt) usos de um conjunto de ácidos nucleicos e de um chip de microarranjo, chip de microarranjo, métodos para detecção de patógenos e/ou microrganismos benéficos em uma amostra orgânica e de tratamento de uma relva doente, e, kit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SOCIETE DES PRODUITS NESTLE S.A. (CH)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF